David S. Block, M.D., has been appointed executive vice president of international operations at DuPont Pharmaceuticals. Previously, Block served as senior vice president of business development and strategic planning. In his new role, he will have
David S. Block, M.D., has been appointed executive vice president of international operations at DuPont Pharmaceuticals. Previously, Block served as senior vice president of business development and strategic planning. In his new role, he will have responsibility for profit and loss in all regions outside the U.S. and will be charged with growing these businesses. Block joined the company in 1990 as a product development manager for central nervous system products. He is also an assistant professor of medicine at Johns Hopkins Hospital in Baltimore and a member of the active attending staff in the Moore Clinic for HIV patients.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.